Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Infinity Pharmaceuticals Inc announces updated phase 1 data showing encouraging clinical activity of IPI-145 in Chronic Lymphocytic Leukemia


Sunday, 8 Dec 2013 10:30am EST 

Infinity Pharmaceuticals Inc:Updates data from a Phase 1 study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with chronic lymphocytic leukemia (CLL), a potentially fatal hematologic malignancy (blood cancer).Says data from the study showed that IPI-145 was highly active in patients with relapsed/refractory CLL, with a nodal response rate of 89 pct and an overall response rate of 48 pct as defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria1.Says including one complete response and 12 partial responses, among patients receiving IPI-145 at doses ≤ 25 mg twice daily (BID).Says onset of activity was rapid, with the majority of responses occurring in less than two months.Says that these data, along with safety data showing that IPI-145 was generally well tolerated, support DUO, Infinity's Phase 3 registration study of IPI-145 in patients with relapsed/refractory CLL, which is now enrolling patients. 

Related Company News

Company Quote

14.4
0.36 +2.56%
17 Sep 2014